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Background: Propranolol and digoxin have been used as first line drugs for treatment of
supraventricular tachycardia (SVT) in infants. Flecainide and other drugs have been
effective as a second line treatment for controlling refractory SVT.
Material and methods: This is a prospective study without randomization and control. The
inclusion criteria were: infants (12 months) with tachyarrhythmia who failed to respond
to first line drugs. Patients having post-surgical arrhythmias were excluded from the study.
Results: A total of 8 infants were treated with flecainide for refractory tachyarrhythmia’s.
Diagnosis on electrocardiogram (ECG) was atrioventricular reentry tachycardia (AVRT) in 5,
atrial ectopic tachycardia (AET) in 2, a combination of AVRT and atrioventricular nodal
reentry tachycardia (AVNRT) in 1. All patients had failed trial of antiarrhythmic drugs prior
to presentation: digoxin and propranolol in 7, amiodarone in 3, cardioversion in 1. Fle-
cainide (80e130 mg/m2 orally) resulted in termination of the tachycardia in all 8 patients.
Acute pharmacological termination of arrhythmia occurred with oral flecainide loading in
1 and temporarily with intravenous esmolol loading in 1 patient. Adjuvant therapy in form
of propranolol was used in 5 and digoxin in 2. There were no side effects noted. Four ep-
isodes of recurrence were noted in 3 patients over 2 years, all of which responded to dose
increase. Mean follow up time is 24.75 months.
Conclusion: This small case series indicates that flecainide is an effective antiarrhythmic
agent, free of side effects and when used orally is capable of terminating and controlling
relatively resistant supraventricular tachycardia in children.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction drugs like flecainide, amiodarone, sotalol or propafenone.Approximately, 60% of children with supraventricular tachy-
cardia (SVT) develop their initial episode by 1 year of age.1
Most often it is managed with a single drug. Spontaneous
resolution occurs in 50e80% of infants by 1 year of age.2 In 10%
of patients, first line drugs in the form of digoxin and/or beta-
blocker may not be effective. These patients need second lineia. Tel.: þ91 9891362233;
, pedsheart@gmail.com.
2013, Cardiological SocieThese drugs can be used either as monotherapy or in combi-
nation for control of tachycardia.3e7 A few patients in this
group may not be controlled with drugs and may rarely
require radiofrequency ablation.
Flecainide has been effective in controlling refractory SVT
when used as a monotherapy or with other antiarrhythmics
in children.3,5e7 Flecainide has been effectively usedfax: þ91 11 26941746.
ty of India. All rights reserved.
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oralmaintenance for prevention of recurrence. Its use has been
variable depending on a variety of factors. In a North American
survey, less than 5% of patients received flecainide.7 In India,
intravenous flecainide is not available while the oral form is
available only at limited locations. We present our experience
with oral flecainide in acute and medium term control of
arrhythmia in infants with SVT not controlled with first line
drugs. Since intravenous flecainide is not available in India, we
used oral flecainide. Sotalol and amiodarone would then have
beenusedas the last line therapy, a strategyusedbyothers too.32. Methods
Data was prospectively collected, however, there was no
randomization and there were no controls. The inclusion
criteria were: infants (12 months) with a diagnosis of
tachyarrhythmia with a failure to control SVT with first line
drugs i.e. propranolol and digoxin in standard dosages and no
history of cardiac surgery. The parameters recorded are
shown in Tables 1 and 2. The QTc was calculated from surface
electrocardiograms using Bazett’s formula.
Echocardiogram was performed on all patients before
initiation of therapy to assess anatomy as well as ventricular
size and function. Twenty-four hour ambulatory ECG moni-
toring (Holter) was done prior to discharge and subsequently
at 1 month follow up and then 3 monthly to assess efficacy of
treatment in the first year of follow up following which at 6
monthly intervals. This was done since follow up only on
basis of history may not be reliable in infants. The objective of
treatment was to get complete suppression of arrhythmia.
Effective control of arrhythmia was defined as complete sup-
pression of tachyarrhythmia on Holter monitoring.3. Results
3.1. Patient profile
A total of 8 patientsmet the inclusion criteria during the study
period (January 2006 to December 2010). The mean age of
patients was 5.1 months with the range of 2 monthse12Table 1 e Study patient profiles.
Patient Age (months) Cardiac anatomy
1 2 Normal
2 3 Ebstein’s
3 2 Normal
4 12 Normal
5 2 Normal
6 12 Normal
7 6 Normal
8 2 Normal
Abbreviations: AVRT ¼ atrioventricular reentry tachycardia, AVNRT ¼ at
cardia, VT ¼ Ventricular tachycardia.
D ¼ digoxin; P ¼ propranolol; E ¼ esmolol; A ¼ amiodarone; CV ¼ cardiovmonths (Table 1). Seven infants had normal ventricular
function by echocardiography and one had an ejection frac-
tion of 40% of left ventricular function (patient no. 3), not low
enough to contraindicate flecainide therapy. The decreased
function was due to tachyarrhythmia associated cardiomy-
opathy which improved completely once the rate was
controlled. At the time of presentation to our institution, all
patients had a failed trial with more than one drug (4 had 2
antiarrhythmics tried, 4 had 3 antiarrhythmics tried and in
addition 1 had attempted cardioversion). All patients were in
tachycardia when they presented to us. Three patients were
on our follow up from neonatal period and had failure of first
line medications when they were included in our study.
3.2. Dosages and monitoring
All patients were hemodynamically stable at presentation;
oral maintenance dose was started in all except one (patient
no. 4) where oral loading of flecainide was performed. Oral
loading was done in the one patient with 120 mg/m2/day of
flecainide divided in three doses over 12 h which resulted in
termination of arrhythmia. No side effects were noted with
oral loading. The median dose of flecainide at initiation of
therapy was 80 mg/m2/day (range 70e100 mg/m2/day) and
was given in two to three divided doses. Corrected QTc in-
terval was noted prior to discharge and subsequently at follow
up visits. The median dose required for the efficacy was
100 mg/m2/day (range: 80e130 mg/m2/day). QTc was not
allowed to increase beyond 0.46 ms and drug dose increase
was stopped if QTc reached or exceeded 0.46 ms.
Efficacy was defined as complete suppression of
arrhythmia. Therapy was initiated in the hospital, and all in-
fants were monitored as inpatients for 3e5 days prior to
discharge. In view of the known interference of milk with
flecainide absorption, we disallowed feeds half an hour before
and after administration of flecainide.8 Dose was adjusted for
the body surface area as the baby grew. The dose was re-
calculated at monthly follow up visits and was rounded off
to convenient dispensing dose (with the dilution of 10 mg/ml).
3.3. Response to therapy
All the patients reverted to normal sinus rhythm (8/8). Sinus
rhythm was restored in less than 3 days in 2/8 patients andECG diagnosis Previous drugs used/
cardioversion
AVRT & AVNRT D,P,A
AVRT D,E,A
AET D,P
AVRT D,P,A
AVRT D,P,CV
AVRT D,P
AVRT D,P, A
AET D,P
rioventricular nodal reentry tachycardia, AET ¼ Atrial ectopic tachy-
ersion.
Table 2 e Response to therapy.
Patient Maximum dosage of
flecainide used mg/m2
Time to complete
control
Additional
drugs used
Length
of f/u (mo)
Recurrences (months
after therapy started)
1 80 3 days P 48 1 (1 mo)
2 120 3 days Eb,P,D,Aa 36 2 (1 mo; 6 mo)
3 100 1 day P,D 24 1 (3 mo)
4 110 1 day e 36 0
5 100 1 day P 12 0
6 200 1 day P 24 0
7 120 1 day P 6 0
8 120 1 day P 12 0
D ¼ digoxin; P ¼ propranolol; E ¼ esmolol; A ¼ amiodarone; mo ¼ months.
a Starred indicates trial of this drug was given but stopped in few weeks.
b Indicates use only on day 1.
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 1 6 8e1 7 1170within 24 h in 6/8 patients. Holter recordings prior to discharge
showed complete control of arrhythmia in 8/8 patients.
Recurrences were noted in 3 patients, 1 month after the
control in one and 3months later in another, whereas in third
patient there were 2 recurrences: the first one occurred after 1
months of follow up and the second after 6 months. All the
recurrences responded to dose increase, none requiring hos-
pitalization. The median duration of therapy was 24 months
(range: 12e48 months). One patient in the series is currently
off all medications and has had no recurrence of arrhythmia
(patient no. 1).
3.4. Additional drugs
Additional drugs were used in 7/8 patients. Esmolol was used
in 1 for acute control of arrhythmia which was continued as
propranolol; propranolol was used in 7/8 patients (inmost as a
continuation of therapy initiated prior to presentation). In 7/8
patients, the desired control was achieved with flecainide and
propranolol combination and in 1 with flecainide alone. In 1
patient (patient no. 2 with Ebstein’s anomaly), amiodarone
was tried for a short period during one of the recurrences
without any effect and was discontinued. The recurrence was
subsequently controlled by increasing the dosage of flecai-
nide. Digoxin was used in 2/6 patients along with propranolol
and flecainide.
3.5. Follow-up
All patients have been in sinus rhythm for a range of 6
monthse48 months (mean 24.75 months). No pro-arrhythmic
side effects were observed with flecainide. There was no
episode of bradycardia or AV block. Echocardiograms
demonstrated normal ventricular function in all infants while
on flecainide. None of the patients had inadvertent prolon-
gation of QTc (>0.48 s). Holter monitoring was performed at a
6 monthly interval did not reveal recurrence of arrhythmia
after the first 3 months in any of the patients except one.4. Discussion
Supraventricular tachycardia in infants is usually controlled
using digoxin or beta-blockers as first line therapy.7 However,in about 10% of infants, second line therapy drugs like flecai-
nide, propafenone, amiodarone or sotalol are needed as single
agents or in combination.3e7 Flecainide has been used as a
second line agent, most often intravenously with a loading
dose which would terminate the arrhythmia, followed by oral
maintenance dosage.9 Though Flecainide is a safe and effec-
tive drug its use ismuch less than anticipated especially in the
North American continent mainly due to the results of the
CAST trial in the late 80’s which showed a significant increase
in mortality with Flecainide in myocardial infarction patients
when it was used to prevent arrhythmias.10 We have in this
paper reported our experience with oral flecainide and noted
good response in a small group of patients. This small study
reinforces that oral flecainide provides a good intermediate
option. There was only one patient in our series that did not
respond to flecainide and went on to require amiodarone for
control of his arrhythmia. Amiodarone has also been studied
as a second line drug.4,11 The intravenous amiodarone study
group conducted a randomized double blinded trial of use of
amiodarone in 61 children. The adverse event rate was 87% in
this group.11 Burri et al reported 23 infants with life-
threatening incessant tachycardia, predominantly supraven-
tricular.4 Intravenous amiodarone was used as a single anti-
arrhythmic agent. In this study, amiodarone was effective in
19/23 infants. Significant side effects were however noted:
neurological side effects in one infant; liver enzyme elevation
necessitating stopping amiodarone administration and sinus
bradycardia requiring dose change in two patients. In
contrast, our small group of patients using flecainide exhibi-
ted no side effects. A staged approach has recently been re-
ported by Drago et al.3 They tried a stepwise protocol on a
study group of 55 infants. Initial treatment was with prop-
afenone, flecainide or propranolol and only if not controlled
with these was amiodarone used.
Only about 30% patients required amiodarone alone or in
combination. Others have tried Flecainide as first line therapy
in newborns and it has worked successfully in 85% of the
babies over a 24 month period.12 Other reports include suc-
cessful control of arrhythmia with a combination of amio-
darone and flecainide or amiodarone and sotalol in this age
group of patients.5,6 In our study, we have used flecainide by
the oral route which has been easy to administer and over-
comes the problem of non-availability of intravenous flecai-
nide in our part of the world. We have used propranolol and
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overlap with flecainide. The limitations of this study include
the small number of patients enrolled. A larger studywould be
required in order to more conclusively validate the use of oral
flecainide. In addition, our patients, though presenting in
tachycardia, were hemodynamically stable. This implies that
there is an internal bias of non-critical patients in our subset.
Non-availability of drug level monitoring has also been a
limitation of this study. Esmolol and oral loading of flecainide
were used when urgent control was required. The advantage
offered by oral flecainide is the ease of administration and the
degree of control of arrhythmia. Significantly, side effects
were not an issue in this series and similar series reported by
other authors using flecainide.4e65. Conclusions
In this study, oral flecainide has been shown to be useful
either alone or in combination as second line management in
difficult to treat arrhythmia in infants less than 12 months
age. Flecainide is safe and has shown good control of the
arrhythmia even when given orally. It has also been safely
administered in small children in this study over a long period
of time. Apart from being useful for acute control, it is also
effective in preventing the recurrence of arrhythmia in ma-
jority of the cases.Conflicts of interest
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